On the human CYP2C9*13 variant activity reduction: a molecular dynamics simulation and docking study.
暂无分享,去创建一个
H. Zhou | Qingchuan Zheng | L. Cai | H Zhou | Y-H Zhou | Q-C Zheng | Z-S Li | Y Zhang | M Sun | C-C Sun | D Si | L Cai | Y Guo | Y. Zhang | D. Si | Y. Guo | Chia-Chung Sun | M. Sun | Y-H Zhou | Z-S Li | H. Zhou
[1] C Masimirembwa,et al. Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function. , 2000, Biochemical and biophysical research communications.
[2] D. Eisenberg,et al. Assessment of protein models with three-dimensional profiles , 1992, Nature.
[3] K Chiba,et al. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. , 1998, Biochemical pharmacology.
[4] Jose Cosme,et al. Crystal structure of human cytochrome P450 2C9 with bound warfarin , 2003, Nature.
[5] T. Kubota,et al. Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele , 2000, European Journal of Clinical Pharmacology.
[6] T. Leemann,et al. Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. , 1993, Life sciences.
[7] F. Guengerich,et al. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. , 2001, Chemical research in toxicology.
[8] D. Mansuy,et al. Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid. , 2003, Archives of biochemistry and biophysics.
[9] P. Bonnabry,et al. Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam , 2004, European Journal of Clinical Pharmacology.
[10] R. Wade,et al. Comparison of the dynamics of substrate access channels in three cytochrome P450s reveals different opening mechanisms and a novel functional role for a buried arginine , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[11] Ilme Schlichting,et al. Structure and chemistry of cytochrome P450. , 2005, Chemical reviews.
[12] D. Zhong,et al. Identification of a novel variant CYP2C9 allele in Chinese. , 2004, Pharmacogenetics.
[13] U. Schwarz,et al. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene , 2003, European journal of clinical investigation.
[14] G. Loew,et al. Homology modeling and substrate binding study of human CYP2C9 enzyme , 1999, Proteins.
[15] D W Nebert,et al. P450 genes: structure, evolution, and regulation. , 1987, Annual review of biochemistry.
[16] Barry C Jones,et al. Development of a combined protein and pharmacophore model for cytochrome P450 2C9. , 2002, Journal of medicinal chemistry.
[17] H. Zhou,et al. Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13 , 2005, Xenobiotica; the fate of foreign compounds in biological systems.
[18] Sason Shaik,et al. Theoretical perspective on the structure and mechanism of cytochrome P450 enzymes. , 2005, Chemical reviews.
[19] Stewart B Kirton,et al. In silico methods for predicting ligand binding determinants of cytochromes P450. , 2004, Current topics in medicinal chemistry.
[20] Yifan Zhang,et al. ROLE OF CYP2C9 AND ITS VARIANTS (CYP2C9*3 AND CYP2C9*13) IN THE METABOLISM OF LORNOXICAM IN HUMANS , 2005, Drug Metabolism and Disposition.
[21] T. Andersson,et al. Analysis of selective regions in the active sites of human cytochromes P450, 2C8, 2C9, 2C18, and 2C19 homology models using GRID/CPCA. , 2001, Journal of medicinal chemistry.
[22] S. Sligar,et al. Electrostatic control of the substrate access channel in cytochrome P-450cam. , 1994, Biochemistry.
[23] Toshimasa Tanaka,et al. Characterization of the CYP3A4 active site by homology modeling. , 2004, Chemical & pharmaceutical bulletin.
[24] D. Mansuy,et al. The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling. , 1995, Biochemistry.
[25] J. Goldstein,et al. Biochemistry and molecular biology of the human CYP2C subfamily. , 1994, Pharmacogenetics.
[26] Kaoru Kobayashi,et al. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. , 2000, Pharmacogenetics.
[27] M. Sutcliffe,et al. Role of conserved Asp293 of cytochrome P450 2C9 in substrate recognition and catalytic activity. , 2003, The Biochemical journal.
[28] Eric F. Johnson,et al. The Structure of Human Cytochrome P450 2C9 Complexed with Flurbiprofen at 2.0-Å Resolution* , 2004, Journal of Biological Chemistry.
[29] C David Stout,et al. Structure of mammalian cytochrome P450 2C5 complexed with diclofenac at 2.1 A resolution: evidence for an induced fit model of substrate binding. , 2003, Biochemistry.
[30] W. L. Jorgensen,et al. Comparison of simple potential functions for simulating liquid water , 1983 .
[31] C. Jang,et al. Allele and genotype frequencies of CYP2C9 in a Korean population. , 2005, British journal of clinical pharmacology.
[32] Xiaoyan Chen,et al. Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. , 2005, British journal of clinical pharmacology.
[33] Erik Eliasson,et al. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro , 2001, European Journal of Clinical Pharmacology.